InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board

InferMed, a leading provider of advanced software solutions for clinical research and practice, has appointed Dr Sally Burtles, Director of Drug Development at Cancer Research UK, as an Observer to the Board.

InferMed has a long-standing relationship with Cancer Research UK, and was backed by the charity at its formation in 1999. A research relationship continues with Cancer Research UK, which remains InferMed's largest institutional shareholder.

Dr Burtles has fifteen years' experience on the Drug Development team at Cancer Research UK, the world's leading independent organisation dedicated to cancer research. In her current position as Director of Drug Development, Dr Burtles is responsible for the strategic planning and operation of Cancer Research UK's new drug evaluation programme.

Dr Burtles previously held the roles of Assistant Director of Drug Development, and Acting Assistant Director of Drug Development (Clinical). She has also been an Invited Visiting Fellow for the National Cancer Institute (NCI) at the USA Food and Drug Administration (FDA).

Prior to joining Cancer Research UK, Dr Burtles was a post-doctoral research scientist at Sandoz AG in Basel. Dr Burtles graduated with a BSc in Biochemistry from the University of St Andrews, Scotland and went on to gain a RT Jones Scholarship to Emory University, Atlanta, Georgia, and then to study for a PhD in Immunology at Bristol University, Bristol, UK.

Commenting on the appointment, Duane Lawrence, CEO of InferMed, said: "With her experience and knowledge of the drug development arena, Dr Burtles will add important insight and perspective to our strategy decisions. We are delighted to welcome her as an Observer to the Board at this important stage in InferMed's development and growth."

About InferMed
InferMed Ltd is a provider of advanced software solutions for clinical research and practice. The Company was founded in 1999, as a spinout from the Imperial Cancer Research Fund's (now Cancer Research UK) Advanced Computational Laboratory, with the mission to commercialise highly advanced software technology developed for clinical research and practice. InferMed's products are currently used across healthcare, pharmaceutical and clinical research sectors worldwide.

InferMed's lead products, MACRO and Arezzo were developed from work started at Cancer Research UK. MACRO supports clinical trials, helping with the collection of data and the management of trial protocols, and is currently being used for over 85,000 patients at more than 400 sites in 36 countries worldwide. Arezzo is highly advanced clinical decision support software designed to aid clinicians through the process of diagnosis and treatment. Arezzo provides active clinical guidelines and protocols at the point-of-care, reducing the risk of misdiagnosis and improving treatment for patients.

Website: www.infermed.com

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...